ライフサイエンスコーパス: withdrawal

1 s, 8 contraindications, and 1 safety-related withdrawal).

2 rom estrogen to simulate postpartum estrogen withdrawal.

3 fault mode network during conditioned heroin withdrawal.

4 , suggesting mPFC-DS overflow of BDNF during withdrawal.

5 xone-precipitated behavioral signs of opiate withdrawal.

6 responses to predator odor during protracted withdrawal.

7 sugar addition and depolymerized upon sugar withdrawal.

8 orrelated negatively with severity of social withdrawal.

9 ("FD-stoppers") before and 8 weeks after PPI withdrawal.

10 ment of compulsive drug taking with repeated withdrawal.

11 ogression, unacceptable toxicity, or patient withdrawal.

12 e a durable benefit for some time even after withdrawal.

13 M sleep quality and quantity after long-term withdrawal.

14 er was rejected soon after immunosuppression withdrawal.

15 nulo-interpeduncular circuit during nicotine withdrawal.

16 t both the rewarding and aversive aspects of withdrawal.

17 rejection in SPK transplants undergoing CNI withdrawal.

18 eas rejections occurring during or after CNI withdrawal.

19 erentiation toward neutrophils upon estrogen withdrawal.

20 moxifen (Tam) as well as to estradiol (E(2)) withdrawal.

21 ly, we examined anxiety-like behavior during withdrawal.

22 ng periods of injection compared to those of withdrawal.

23 prefrontal cortex (mPFC) following nicotine withdrawal.

24 increased success of immunosuppression (IS) withdrawal.

25 ays of anxiety and anhedonia during estrogen withdrawal.

26 acceptable toxicity, disease progression, or withdrawal.

27 tructure in Ada(-/-) mice post two-week drug withdrawal.

28 utilization to treat opioid use disorder and withdrawal.

29 luding for up to 40 days following rapamycin withdrawal.

30 d as a function of trait addiction and state withdrawal.

31 gdala critically involved in both stress and withdrawal.

32 he pathophysiology of alcohol dependence and withdrawal.

33 nce biomarkers were predictive of successful withdrawal.

34 sed to its pretreatment level upon treatment withdrawal.

35 or less leading to a dose reduction or drug withdrawal.

36 nimals after cocaine self-administration and withdrawal.

37 rsive symptoms experienced by addicts during withdrawal.

38 ence and virological relapse after treatment withdrawal.

39 optotic molecule Hrk in response to cytokine withdrawal.

40 ell-cell boundary correlates with microspike withdrawal.

41 nce biomarkers were predictive of successful withdrawal.

42 either naloxone-precipitated or spontaneous withdrawal.

43 (MGF), the command-like interneuron for head withdrawal.

44 nd what may serve to improve REM sleep after withdrawal.

45 l as predictors of successful mTOR-I therapy withdrawal.

46 or's decision to discontinue, or participant withdrawal.

47 ular disease complications, leading to trial withdrawal.

48 it still accounts for a third of total water withdrawals.

49 ceased pumping (50-60%) and exhibited tissue withdrawal (10-25%).

50 ity, which partially recovered in protracted withdrawal (2 weeks).

51 lite withdrawal (68%), calcineurin inhibitor withdrawal (23%), hydroxychloroquine (71%), antibiotics

52 Following glucose withdrawal, 5' binding was abolished within 30 s, explai

53 erapeutic management included antimetabolite withdrawal (68%), calcineurin inhibitor withdrawal (23%)

54 a structural decomposition analysis of water withdrawals across eight different crops and six livesto

55 erstand whether inhaled corticosteroid (ICS) withdrawal affected IMPACT results, given direct transit

56 How estrogen withdrawal affects oxytocin (OT) neurocircuitry has not

57 During acute withdrawal, AIE altered LTD induced by the group I mGluR

58 n-like behaviors, including somatic signs of withdrawal, allodynia, anxiety-like behavior, and relaps

59 e affect during acute and protracted alcohol withdrawal and following stress in adulthood.

60 t site for mediating the somatic symptoms of withdrawal and for regulating alcohol intake.

61 ible that bouts of sleepiness lead to social withdrawal and loneliness, both risk factors for mental

62 ective treatment for patients seeking opioid withdrawal and nonagonist treatment for preventing relap

63 sensitive to metabolic stress such as serum withdrawal and restrictive feeding.

64 al trials (AMAGINE -1 [Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate t

65 e, morphine-induced locomotor sensitization, withdrawal and supra-spinal analgesia were facilitated,

66 for disorder remission, adverse events, and withdrawals and as standardised mean differences (SMDs)

67 ssive alcohol intake, sensitized by repeated withdrawal, and contribute to the development of addicti

68 rescription drug, is prone to misuse, abuse, withdrawal, and dependence.

69 ictors of severe ALT flares, after treatment withdrawal, and HBV DNA reactivation.

70 alanine transaminase flares, after treatment withdrawal, and HBV-DNA reactivation.

71 heroin delivery, followed by 2 weeks of drug withdrawal, and then reinstated to heroin-conditioned cu

72 capacity, contribute to irreversible tissue withdrawal, and weaken skeletal strength and stiffness o

73 bances caused by chronic opioid exposure and withdrawal are less well-understood.

74 physical and psychologic symptoms of opiate withdrawal are well-documented, sleep disturbances cause

75 changes in adenosine levels in plasma during withdrawal as a surrogate for brain adenosine, which pla

76 natant reduced nociceptive behavior in a paw withdrawal assay, supporting a role for exosomes in canc

77 mus (EVR + rTAC; n = 52) with corticosteroid withdrawal at 6-month posttransplant or continue mycophe

78 -exposure CNI (cyclosporine) followed by CNI withdrawal at week 7-11 posttransplant or (2) standard-e

79 oven findings disqualifying patients from IS withdrawal attempt were factors associated with dnDSA de

80 eta4*nAChRs have been implicated in nicotine withdrawal, aversion, and reinforcement.

81 cohort C had detectable HBV RNA at treatment withdrawal, but HBcrAg and HBV DNA were not detected.

82 ontrast to buprenorphine, which can suppress withdrawal, but produces and maintains morphine antinoci

83 ong-term opioid use or are modified by acute withdrawal, but research on long-term consequences of op

84 use, and no evidence of dependence or opioid withdrawal by AEs or objective measures.

85 ion, and subsequently mature after prolonged withdrawal by recruiting AMPARs, echoing acquisition and

86 a TAF-based regimen met confirmed virologic withdrawal criteria, with no emergent resistance at fail

87 x healthy subjects participated in an A-B-A (withdrawal design) study protocol, which involved leanin

88 splantation, but its off-target effects make withdrawal desirable.

89 Alcohol dependence and protracted withdrawal did not alter either 5-HT1A-mediated decrease

90 This study evaluated IS withdrawal directly from mTOR-I therapy in LTRs and achi

91 tary rewards cues both ON and OFF (overnight withdrawal) dopamine medication, as indexed by pupillary

92 Glucose withdrawal downregulated pMLC, and coupled with hypoxia,

93 m rates of serious adverse events (1.9%) and withdrawal due to adverse events (0.4%).

94 l therapy was associated with higher risk of withdrawal due to adverse events vs placebo or no antivi

95 Drug-related grade >=2 adverse events and withdrawals due to adverse events occurred in 17 (4.6%)

96 ent, fractures, falls, syncope, hypotension, withdrawals due to adverse events, and acute kidney inju

97 erence, 4% [range, 2% to 4%]), and increased withdrawals due to adverse events.

98 spitalizations, musculoskeletal injuries, or withdrawals due to adverse events.

99 Compliance was high (96.9%), and withdrawals due to treatment-related adverse events were

100 both chronic alcohol exposure and protracted withdrawal dysregulate 5-HT signaling in the CeA.

101 iol (E2) and symptom-provoking effects of E2-withdrawal (E2-WD) suggest that a greater sensitivity to

102 mented by stress/negative mood induction and withdrawal-effects amplified in those with psychiatric s

103 Early steroid withdrawal (ESW) is associated with acceptable outcomes

104 Early steroid withdrawal (ESW) is associated with AR in other populati

105 under belatacept-based early corticosteroid withdrawal following T-cell-depleting induction in a rec

106 s associated with an increased likelihood of withdrawal for any reason (OR 2.61, 95% CI: 1.38-4.96) o

107 ical and histologic relapse and no premature withdrawal for any reason.

108 ear; 3) a conditional recommendation for ICS withdrawal for patients with COPD receiving triple thera

109 orphine-dependent, or have undergone 4 wk of withdrawal from chronic morphine exposure, relative to s

110 decreases cue-induced cocaine seeking after withdrawal from cocaine self-administration and cue-indu

111 Rats undergoing withdrawal from cocaine showed an accumulation of H3Q5do

112 We found that 3 weeks after withdrawal from cocaine, LH MCH neurons exhibit a wide r

113 he VP and whether its effects are altered by withdrawal from cocaine.

114 may indicate a complex role for dynorphin in withdrawal from cocaine.SIGNIFICANCE STATEMENT The ventr

115 Withdrawal from drugs has been shown to induce drastic s

116 tional or motivational signs and symptoms of withdrawal from drugs of abuse.

117 elated with freedom from rejection following withdrawal from immunosuppression in a clinical trial of

118 Exposure to predator odor during protracted withdrawal from intermittent alcohol drinking resulted i

119 strong compared to WU-AX, resulting in water withdrawal from starch during resting.

120 hypoferremic response in flies, namely, iron withdrawal from the hemolymph and accumulation in the fa

121 Deprivation of glutamine by glutamine-withdrawal, GLS knockdown, or exposure to the GLS inhibi

122 tion nor bidirectional manipulation of acute withdrawal impacted the subsequent enhancement in fear l

123 these data suggest that spontaneous nicotine withdrawal impairs distinct components of cognitive set-

124 crease in drug seeking following a period of withdrawal in chronically food-restricted rats compared

125 ; P < 0.0001) concentrations during nicotine withdrawal in comparison with nicotine sated state.

126 atically examined the effects of spontaneous withdrawal in mice exposed to either nicotine (6.3 or 18

127 ormed a prospective trial of SRL monotherapy withdrawal in nonimmune, nonviremic LTRs > 3 years post-

128 asibility and safety of neurohumoral blocker withdrawal in patients with normalized ejection fraction

129 studies of immunosuppression minimization or withdrawal in solid organ transplantation.

130 mulated pseudopregnancy followed by estrogen withdrawal in Syrian hamsters, a first for this species.

131 Areas for future research include managing withdrawal in the context of stabilising patients with o

132 iods experienced an overall decline in water withdrawals in the production of all crops except oilsee

133 To minimize impact from ICS withdrawal, in an analysis excluding the first 30 days,

134 t standards of care for medically supervised withdrawal include treatment with mu-opioid receptor ago

135 yperconjugation as protecting group electron withdrawal increases.

136 cts (increase and decrease) after protracted withdrawal indicative of neuroadaptations of presynaptic

137 Intra-BNST PACAP(6-38) also reversed ethanol withdrawal-induced anxiety-like behavior in ethanol-depe

138 and its cognate receptor, PAC1R, in alcohol withdrawal-induced behaviors.

139 D are characterized by drinking to alleviate withdrawal-induced negative emotional states.

140 Estrogen withdrawal induces OT neuroplasticity in the paraventric

141 The LTP-triggered PAP withdrawal involves NKCC1 transporters and the actin-con

142 The treatment of opioid withdrawal is an important area of clinical concern when

143 t support the conclusion that successful Tac withdrawal is not simply due to absence of donor-reactiv

144 cy and efficacy, whereas the onset of opioid withdrawal is prevented.

145 y dosing with rhbeta-Gal, followed by enzyme withdrawal, is sufficient to augment beta-Gal activity l

146 alculated as the change in cold pressor hand withdrawal latency (HWL) before and after drug injection

147 In both instances serum withdrawal leads to increased activating PRK1 and PRK2 p

148 of persisters from dormancy after antibiotic withdrawal leads to recurrent infection.

149 io operant self-administration sessions, and withdrawal-like irritability through the bottle brush te

150 Cognitive deficits during nicotine withdrawal may contribute to smoking relapse.

151 , high-intensity stimuli triggered a process withdrawal mediated by both P2Y1 and P2Y13 receptors.

152 Upon guselkumab withdrawal, most patients lost clinical response and reg

153 scratching, laminae II/III INs generate paw withdrawal movements, and laminae III/IV INs modulate dy

154 completion of 10 cycles (n = 3), and consent withdrawal (n = 1).

155 tion blockade (belatacept) with intended CNI withdrawal (n = 22).

156 During the withdrawal/negative affect stage, there is a decrease in

157 hin a three-stage cycle: binge/intoxication, withdrawal/negative affect, and preoccupation/anticipati

158 ersistent REM sleep impairment after cocaine withdrawal negatively impacts relapse-like behaviors in

159 sation group were excluded because of either withdrawal, no response, or no follow-up data at 6, 12,

160 taneous coronary intervention (PCI) involves withdrawal of acetylsalicylic acid (ASA), or aspirin, wh

161 s unknown and little data exist to guide the withdrawal of anaesthetics in refractory status epilepti

162 Premature withdrawal of anaesthetics risks the recurrence of seizu

163 ptor antagonist) infusion following a 2-week withdrawal of anti-hypertensive medications.

164 Adverse events that led to withdrawal of any agent occurred in 156 (34%) patients i

165 esent, was not reactivated despite temporary withdrawal of ART.

166 Withdrawal of basic or hydrophobic amino acids induces t

167 ensin-aldosterone system inhibitors, n = 20; withdrawal of beta-blockers, n = 20; and withdrawal of r

168 All patients expired after withdrawal of care due to lack of response to CAR-T ther

169 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses durin

170 it prematurely because of loss to follow-up, withdrawal of consent, investigator decision, and an unr

171 disease progression, unacceptable toxicity, withdrawal of consent, or physician decision.

172 isease recurrence, unacceptable toxicity, or withdrawal of consent.

173 sease progression, unacceptable toxicity, or withdrawal of consent.

174 isease progression, intolerable toxicity, or withdrawal of consent.

175 unacceptable toxicity, loss to follow-up, or withdrawal of consent.

176 d owing to either poor clinical condition or withdrawal of consent.

177 nt with hippocampal remyelination induced by withdrawal of Cup/Rap, proliferation of type 1 NSCs and

178 Withdrawal of doxycycline in the middle of 3D culture re

179 Withdrawal of GABA(A) receptor-mediated inhibition of th

180 as living organ donation prior to a planned withdrawal of life-sustaining care in an imminently dyin

181 ncy of directives and associated withholding/withdrawal of life-sustaining care.

182 level of care decisions and the incidence of withdrawal of life-sustaining therapies.

183 Do not resuscitate (DNR) and withdrawal of life-sustaining therapy (WLST) order statu

184 tus, Charlson Comorbidity Index, and time to withdrawal of life-sustaining therapy.

185 essimistic prognostication could lead to the withdrawal of life-sustaining treatment in patients who

186 receive dialysis, but had longer duration to withdrawal of lifesustaining therapy.

187 own about the risk of clinical relapse after withdrawal of NA.

188 (Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally

189 novalent OPV2 in Antwerp, done before global withdrawal of OPV2, and the second was a phase 2 study i

190 nism, long-term potentiation (LTP), triggers withdrawal of PAPs from potentiated synapses.

191 nti-PD1 therapy in cHL that is suggestive of withdrawal of prosurvival factors, rather than induction

192 ion of neurohumoral blocker therapy, n = 20; withdrawal of renin-angiotensin-aldosterone system inhib

193 20; withdrawal of beta-blockers, n = 20; and withdrawal of renin-angiotensin-aldosterone system inhib

194 actorial design, subjects were randomized to withdrawal of renin-angiotensin-aldosterone system inhib

195 receptor, which has been linked with process withdrawal of rodent cells.

196 d at least 2 days (5 +/- 2 d) after complete withdrawal of sedation.

197 an alternative treatment option that enables withdrawal of steroids as well as reduction of CNIs for

198 e sodium, or mycophenolate mofetil and rapid withdrawal of steroids.

199 After withdrawal of tamoxifen, BrdU-positive ZCs reappeared.

200 The administration and withdrawal of the combination of cuprizone and rapamycin

201 The study was terminated after withdrawal of the device's European Conformity marking b

202 ciated with weight gain, possibly reflecting withdrawal of the inhibitory effect of higher efavirenz

203 rned by the timing of the seasonal onset and withdrawal of the Intertropical Convergence Zone, which

204 Withdrawal of the metabolism inhibitors restored the cyt

205 The withdrawal of the serotype 2 component of oral polioviru

206 precedes cell death and is reversible after withdrawal of the stress condition and the PI3K inhibito

207 The withdrawal of TKI from addicted tumors in vitro and in v

208 onstrated by the lack of viral rebound after withdrawal of treatments, and by adoptive transfer of tr

209 intervention if the surgery was "off-track" (withdrawal of trust); (6) re-evaluation of trust for fut

210 Withdrawal of VKAs and high-dose vitamin K2 improve vita

211 ess defined by periods of heavy drinking and withdrawal, often leading to a chronic relapsing course.

212 ronic nicotine dependence and acute nicotine withdrawal on cognitive control are poorly understood.

213 The effects of withdrawal on sleep may be related to the loss of alcoho

214 to model the effects of postpartum estrogen withdrawal on the brain and anxiety-like behavior.

215 ts, we also explored the effects of nicotine withdrawal on these neurochemical substrates.

216 gs, abstract views, downloads, comments, and withdrawals on the medRxiv preprint server from June 201

217 d stable kidney transplant recipients to Tac withdrawal or maintenance of standard immunosuppression

218 appeared safe; no definitely vaccine-related withdrawals or serious adverse events were reported.

219 ration chambers and were subjected to a 14 d withdrawal period while sated (unlimited access to food)

220 During the randomized-withdrawal period, there were too few recurrence events

221 e days, after which they underwent a 1-month withdrawal period.

222 in the dorsal raphe nucleus during estrogen withdrawal prevented the high-anxiety behavioral phenoty

223 imals raises the possibility of progesterone withdrawal prior to parturition.

224 During acute withdrawal, rats exposed to chronic intermittent ethanol

225 it that contributes to learning in defensive withdrawal reflexes in Aplysia californica, we investiga

226 ch ALK overactivity drives toxicity upon TKI withdrawal remained obscure.

227 Mice undergoing nicotine withdrawal required more trials to attain strategy-switc

228 of addiction, consisting of desensitization, withdrawal, resensitization, and associated changes in n

229 95% CI: 0.37-1.91) for the first and second withdrawal, respectively.

230 circuit plays a central role in the nicotine withdrawal response.

231 progresses into a vicious cycle of abuse and withdrawal, resulting in very high rates of relapse.

232 mice, with diminished tolerance, dependence/withdrawal, reward liability, and respiratory depression

233 tations as measured by the Wisconsin Smoking Withdrawal Scale (P = 0.04) and Tobacco Craving Question

234 -HT system to chronic alcohol and protracted withdrawal.SIGNIFICANCE STATEMENT Elevated GABA signalin

235 underlying the aversive symptoms seen after withdrawal.SIGNIFICANCE STATEMENT The biggest problem in

236 software platform, PAWS (Pain Assessment at Withdrawal Speeds), uses a univariate projection of paw

237 This withdrawal state manipulation also led to an increase in

238 rtum drop in estrogen results in an estrogen withdrawal state that is related to changes in affect, m

239 ng and anxiety-like behavior observed during withdrawal, suggesting that this system represents a maj

240 was negatively correlated with the change in withdrawal symptom manifestations as measured by the Wis

241 dicated a significant interaction of alcohol withdrawal symptom score by treatment by full-dose treat

242 eavy use increases the likelihood of alcohol withdrawal symptoms and associated secondary outcomes of

243 and buprenorphine act by suppressing opioid withdrawal symptoms and attenuating the effects of other

244 lower abuse liability and induced relief of withdrawal symptoms and drug cravings, despite acting on

245 The findings indicate that alcohol withdrawal symptoms are a significant moderator of prazo

246 e data support further evaluation of alcohol withdrawal symptoms as a prognostic indicator of prazosi

247 dence (N=100) with varying levels of alcohol withdrawal symptoms assessed at treatment entry.

248 alities are often a prominent contributor to withdrawal symptoms following chronic drug use.

249 The authors examined whether alcohol withdrawal symptoms moderate the efficacy of prazosin in

250 Individuals with high alcohol withdrawal symptoms on prazosin compared with placebo al

251 By week 12, participants with high alcohol withdrawal symptoms on prazosin reported 7.07% heavy dri

252 rthermore, NFP produced significantly lesser withdrawal symptoms than naloxone at similar doses.

253 pically sudden onset, severe, and protracted withdrawal symptoms when medication was stopped.

254 bserved in those reporting low or no alcohol withdrawal symptoms.

255 ics of intoxication or by characteristics of withdrawal symptoms.

256 lcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial.

257 due to the aversive aspects of the nicotine withdrawal syndrome (NWS), which remains poorly understo

258 he patients had signs and symptoms of opioid withdrawal syndrome during evaluation.

259 resistance to enzalutamide and enzalutamide withdrawal syndrome have been reported.

260 tically ill patients including pain, alcohol withdrawal syndrome, status epilepticus, and acute agita

261 pain, sedation, status asthmaticus, alcohol withdrawal syndrome, status epilepticus, and acute behav

262 shown to be active in vivo, do not manifest withdrawal syndromes or reward behavior in conditioned-p

263 consumption and a high risk of relapse after withdrawal that are thought to result from persistent ad

264 e intensification of aversive feelings after withdrawal that involves the glutamatergic neurons of th

265 ow that, on memory retrieval after prolonged withdrawal, the matured silent synapses become AMPAR-sil

266 effects of the following SCS patterns on paw withdrawal threshold and resting state EEG theta power a

267 ded in the spinal nerves, as well as the paw withdrawal threshold.

268 duction in hind paw and orofacial mechanical withdrawal thresholds as a surrogate readout of allodyni

269 lation-related changes in mechanical or heat withdrawal thresholds or in capsaicin-induced nocifensiv

270 d nearly complete recovery of mechanosensory withdrawal thresholds.

271 ly, our data suggest a role for dynorphin in withdrawal through its actions in the VP.

272 no significant difference between groups in withdrawal time (417 +/- 101 seconds for the CADe group

273 A minimum withdrawal time of 6 minutes was required.

274 onoscopy, non-neoplastic resection rate, and withdrawal time.

275 detected per colonoscopy without increasing withdrawal time.

276 Total procedure and withdrawal times with pancolonic chromoendoscopy (30.7 +

277 earning processes in the form of conditioned withdrawal to facilitate relapse to compulsive-like drug

278 After doxycycline withdrawal, transgenic TDP-43(A315T) expression graduall

279 rallel-group, enriched enrollment randomized withdrawal trial conducted at the Medical University Inn

280 nter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in patients with acute sy

281 omized trial (Belatacept-based Early Steroid Withdrawal Trial, clinicaltrials.gov NCT01729494) to det

282 reening biopsy to enter an immunosuppression withdrawal trial.

283 ity of life, which often culminate in social withdrawal, unemployment, depression and suicidal though

284 Whereas failed withdrawal upregulated immune activation genes, successf

285 profiling of LH MCH neurons after long-term withdrawal using RNA-sequencing, and performed functiona

286 us opioids and engage dramatic tolerance and withdrawal via molecular and neurocircuitry neuroadaptat

287 ated immune activation genes, successful Tac withdrawal was associated with a downregulatory and proa

288 However, neurohumoral blocker withdrawal was hampered by cardiac comorbidities.

289 HBcrAg and HBV RNA at the time of treatment withdrawal was only observed in those patients who devel

290 adverse events and adverse events leading to withdrawal was similar between groups.

291 as indexed by the intensity of precipitated withdrawal, was fully statistically moderated by a predi

292 By reducing H3Q5dop in the VTA during withdrawal, we reversed cocaine-mediated gene expression

293 trol and treatment arm loss to follow-up and withdrawal were 24% and 23%, respectively.

294 Enrollment and CNI withdrawal were stopped after 43/60 planned subjects had

295 SER3 is de-repressed by serine withdrawal, which leads to shut-off of SRG1 synthesis.

296 e effects of cannabis use, intoxication, and withdrawal while also reviewing the developmental pathwa

297 Eight of 14 subjects attempted but failed withdrawal, while six developed stable graft function fo

298 uate the impact of manipulating sleep during withdrawal, will further our understanding of the cyclic

299 activity increase REM sleep after long-term withdrawal with important differences.

300 nor-reactive immunity in subjects who failed withdrawal without evidence of regulatory T cell dysfunc